Novavax blamed its shrinking revenue forecast on “several evolving market dynamics,” namely related to demand for the company’s COVID-19 vaccine falling short of expectations. One key reason why was the time it took for Novavax to bring its Nuvaxovid
vaccine to market, which at roughly two years was more than a year longer than either the Pfizer/BioNTech combination or Moderna needed to develop their messenger RNA (mRNA)-based COVID-19 vaccines . . .
See More on the Edge
Continue reading this article and more
with a GEN Edge subscription
The post StockWatch: Novavax Sinks with Revenue Forecast, Vaccine Demand appeared first on GEN – Genetic Engineering and Biotechnology News.
